Danaher Corporation (DHR) Debt to Equity Ratio: 0.35
Is Danaher Corporation’s debt to equity ratio high or low?
Danaher Corporation's debt to equity ratio of 0.35 is 18% below its 5-year average of 0.43, near the low end of its 5-year range (0.35–0.56).
The debt to equity ratio for Danaher Corporation (DHR) is 0.35 as of Tuesday, June 9, 2026. It is equal to its 12-month average by 0.00% (0.35).
DHR Debt to Equity Ratio Chart
DHR Average Debt to Equity Ratio Chart
DHR Current vs Average Debt to Equity Ratio Chart
DHR Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.35
DEBT TO EQUITY RATIO AVG TTM
0.35
DEBT TO EQUITY RATIO AVG 3Y
0.37
DEBT TO EQUITY RATIO AVG 5Y
0.43
DEBT TO EQUITY RATIO AVG 10Y
0.47
DEBT TO EQUITY RATIO AVG 15Y
0.39
DEBT TO EQUITY RATIO AVG 20Y
0.37
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
-5.41%
CURRENT VS 5Y AVG
-17.97%
CURRENT VS 10Y AVG
-24.80%
CURRENT VS 15Y AVG
-10.11%
CURRENT VS 20Y AVG
-5.04%
DHR Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Danaher Corporation (DHR) | — | 0.35 | 0.35 | 0.37 | 0.43 |
| CVS Health Corporation (CVS) | $123.84B | 1.24 | 1.17 | 1.09 | 1.10 |
| Pfizer Inc. (PFE) | $146.48B | 0.78 | 0.77 | 0.68 | 0.63 |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 0.02 | 0.01 | 0.01 | 0.01 |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 2.55 | 2.84 | 2.10 | 1.84 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $113.14B | 0.21 | 0.16 | 0.11 | 0.11 |
| Gilead Sciences, Inc. (GILD) | $155.82B | 1.09 | 1.23 | 1.19 | 1.29 |
| Abbott Laboratories (ABT) | $158.94B | 0.29 | 0.30 | 0.38 | 0.44 |
| Medtronic plc (MDT) | $105.25B | 0.00 | 0.29 | 0.39 | 0.42 |
| Elevance Health Inc. (ELV) | $92.17B | 0.76 | 0.78 | 0.74 | 0.71 |
Financial Health
Debt/Equity
0.35
Current Ratio
1.87
Danaher Corporation Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Danaher Corporation Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Danaher Corporation (DHR)?
- The debt to equity ratio for DHR stock is 0.35.
- Is Danaher Corporation's debt to equity ratio high or low?
- Danaher Corporation's debt to equity ratio of 0.35 is 18% below its 5-year average of 0.43, near the low end of its 5-year range (0.35–0.56).
- What is the TTM average debt to equity ratio for Danaher Corporation (DHR)?
- The TTM average debt to equity ratio for DHR stock is 0.35.
- What is the 3Y average debt to equity ratio for Danaher Corporation (DHR)?
- The 3Y average debt to equity ratio for DHR stock is 0.37.
- What is the 5Y average debt to equity ratio for Danaher Corporation (DHR)?
- The 5Y average debt to equity ratio for DHR stock is 0.43.
- What is the 10Y average debt to equity ratio for Danaher Corporation (DHR)?
- The 10Y average debt to equity ratio for DHR stock is 0.47.
- What is the 15Y average debt to equity ratio for Danaher Corporation (DHR)?
- The 15Y average debt to equity ratio for DHR stock is 0.39.
- What is the 20Y average debt to equity ratio for Danaher Corporation (DHR)?
- The 20Y average debt to equity ratio for DHR stock is 0.37.
Danaher Corporation Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.35 |
| 2024-12-31 | 0.35 |
| 2023-12-31 | 0.37 |
| 2022-12-31 | 0.41 |
| 2021-12-31 | 0.52 |
| 2020-12-31 | 0.56 |
| 2019-12-31 | 0.74 |
| 2018-12-31 | 0.35 |
| 2017-12-31 | 0.40 |
| 2016-12-31 | 0.53 |
| 2015-12-31 | 0.54 |
| 2014-12-31 | 0.15 |
| 2013-12-31 | 0.16 |
| 2012-12-31 | 0.28 |
| 2011-12-31 | 0.31 |
| 2010-12-31 | 0.21 |
| 2009-12-31 | 0.25 |
| 2008-12-31 | 0.27 |
| 2007-12-31 | 0.41 |
| 2006-12-31 | 0.37 |
| 2005-12-31 | 0.21 |
| 2004-12-31 | 0.29 |
| 2003-12-31 | 0.36 |
| 2002-12-31 | 0.44 |
| 2001-12-31 | 0.53 |
| 2000-12-31 | 0.41 |
| 1999-12-31 | 0.22 |
| 1998-12-31 | 0.35 |
| 1997-12-31 | 0.22 |
| 1996-12-31 | 0.30 |
Related Metrics
About Danaher Corporation
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Rainer Blair